Use of Two-Dimensional Nanomaterial in Inhibition of Coronavirus
Summary
USPTO granted Patent US12611385B2 to Shenzhen Institutes of Advanced Technology on April 28, 2026, covering the use of two-dimensional nanomaterials (CIPS nanosheet, graphene oxide nanosheet, molybdenum disulfide nanosheet, black phosphorus nanosheet, or mixtures thereof) in the inhibition of coronaviruses including HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, SARS-CoV2, and MERS-CoV. The patent also covers the preparation of medicaments for treating or preventing diseases caused by coronavirus infection using these nanomaterials. The filing date was February 22, 2021, with 9 claims granted.
“Provided is the use of two-dimensional nanomaterials in the inhibition of a coronavirus, and specifically disclosed is the use of the two-dimensional nanomaterials in the preparation of a medicament for treating or preventing diseases caused by a coronavirus or of a material for adhering to or inhibiting the coronavirus.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
USPTO issued Patent US12611385B2 granting Shenzhen Institutes of Advanced Technology exclusive rights to the use of specified two-dimensional nanomaterials for inhibiting coronaviruses and preparing coronavirus treatment medicaments. The patent lists five nanomaterial types (CIPS nanosheet, graphene oxide nanosheet, molybdenum disulfide nanosheet, black phosphorus nanosheet, and mixtures) effective against seven coronavirus strains including SARS-CoV-2. Nine claims were granted.
Parties seeking to commercialize coronavirus inhibitors or treatments using these specific 2D nanomaterials should conduct freedom-to-operate analysis to assess potential infringement of this newly granted patent. The assignee's geographical scope is US patent protection only; international protection would require separate filings in relevant markets.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of two-dimensional nanomaterial in inhibition of coronavirus
Grant US12611385B2 Kind: B2 Apr 28, 2026
Assignee
SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY;
Inventors
Yang Li, Liming Wang, Guofang Zhang
Abstract
Provided is the use of two-dimensional nanomaterials in the inhibition of a coronavirus, and specifically disclosed is the use of the two-dimensional nanomaterials in the preparation of a medicament for treating or preventing diseases caused by a coronavirus or of a material for adhering to or inhibiting the coronavirus. The two-dimensional nanomaterial is selected from the group consisting of copper indium thiophosphate (CIPS) nanosheet, graphene oxide nanosheet, molybdenum disulfide nanosheet, black phosphorus nanosheet and mixtures thereof. The coronavirus is selected from one of HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, SARS-CoV2 or MERS-CoV. The diseases caused by the coronavirus are diseases caused by coronavirus infection. The material has the advantages of being simple to prepare, having a high biological safety and an excellent effect.
CPC Classifications
A61K 9/7007 A61K 33/24 A61K 33/42 A61K 33/44 A61K 45/06 A61K 8/19 A61K 8/24 A61K 33/30 A01N 25/34 A01N 59/00 A01N 59/16 A01N 59/26 A01P 1/00 A61P 31/14 B82Y 5/00 Y02A 50/30 C09D 5/14 C11D 3/48 C11D 3/12 A41D 31/30 A61Q 19/10 B01D 39/20 B01D 46/00 B65D 65/38
Filing Date
2021-02-22
Application No.
18267783
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.